Global Stem Cell Therapy Market 2020 Trends Analysis and Coronavirus (COVID-19) Effect Analysis | KEY PLAYERS MARKET WITH COVID-19 Impact Analysis, In…

The globalStem Cell Therapy marketreport has been updated by theMarket Data Analyticsowing to the changed market conditions because of COVID-19. Although, the world is still in hope that everything will come back to normal but the WHO finds no positive signs. The WHO has clearly mentioned that people will have to start living with this disease as there are very less chances that the coronavirus infection will go. The conditions in the global market have changed drastically and every single country is facing economic crunch owing to the slowing down of the business. Thus, it was necessary to update the Stem Cell Therapy market report.

Click Here To Access The Free Sample PDF Report (including COVID19 Impact Analysis, full TOC, Tables and Figures)@https://www.marketdataanalytics.biz/worldwide-stem-cell-therapy-market-report-2020-industry-analysis-34962.html#request-sample

The latest report consists of the following parts:

Part 1 In the first part of the Stem Cell Therapy market report the market introduction or the market overview is included. In this part the target audience for the Stem Cell Therapy market is also defined for better understanding the market and clients.

Part 2 In the second part the research methodologies and the market tools that were incorporated for studying the market is explained in detail. There are also details about the primary and secondary researches that were conducted by the research analysts.

Read Detailed Index of full Research Study at::https://www.marketdataanalytics.biz/worldwide-stem-cell-therapy-market-report-2020-industry-analysis-34962.html

Part 3 In the third part the qualitative information about the Stem Cell Therapy market is included. This information is mainly about the Stem Cell Therapy market drivers, restraints, opportunities, and challenges.

Part 4 The fourth part of the report deals with the market segmentation. The Stem Cell Therapy market includes the following segmentations:{Autologous, Allogeneic};{Musculoskeletal Disorder, Wounds & Injuries, Cornea, Cardiovascular Diseases, Others}. A detailed analysis of every single category in the market segments has been included. The data includes both statistics and qualitative information which are depicted in the form of tables and figures in the report.

Part 5 Geographical presence of the Stem Cell Therapy market in the major regions such as North America, Europe, Latin America, Asia Pacific, and the Middle East and Africa is described in detail.

Part 6 The major market players in the Stem Cell Therapy market includeOsiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCRPharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix). Along with these many other industry players are profiled in this section.

Part 7 The last part deals with the market conclusions. The conclusions mainly include the observations and the comments from the research analysts and the market experts.

For Any Query Regarding the Stem Cell Therapy Market Report? Contact Us at:https://www.marketdataanalytics.biz/worldwide-stem-cell-therapy-market-report-2020-industry-analysis-34962.html#inquiry-for-buying

Note In order to provide a more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

Continue reading here:
Global Stem Cell Therapy Market 2020 Trends Analysis and Coronavirus (COVID-19) Effect Analysis | KEY PLAYERS MARKET WITH COVID-19 Impact Analysis, In...

Forecast On Stem Cell Reconstructive Market Global Industry Analysis and Trends till 2028 – Bulletin Line

A new intelligence report Stem Cell Reconstructive Market has been Lately Added into Adroit Market Research collection of top-line market research reports. Global Stem Cell Reconstructive Market report is a meticulous comprehensive analysis of this market that provides access to direct first-hand insights on the growth trail of market in near term and long term. On the basis of factual advice sourced from authentic industry pros and extensive main industry research, the report provides insights about the historical growth pattern of Stem Cell Reconstructive Market and current market situation. It then provides short- and long-term market development projections.

Projections are purely based on the detailed analysis of key Market dynamics that are expected to influence Stem Cell Reconstructive Market performance and their intensity of impacting market growth within the span of assessment period.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2694263&source=atm

In addition to evaluation of dynamics, the report provides In-depth examination of key business trends that are expected to act more prominently in global Stem Cell Reconstructive Market. The study also provides valued information about the present and upcoming growth opportunities in Stem Cell Reconstructive Market the important players and new market entrants can capitalize on.

Competitive companies And manufacturers in global market

segment by Type, the product can be split into Embryonic Stem Cell Adult Stem Cell Market segment by Application, split into Hospitals Research Institutes Others

Market segment by Regions/Countries, this report covers North America Europe China Japan Southeast Asia India Central & South America

The study objectives of this report are: To analyze global Stem Cell Reconstructive status, future forecast, growth opportunity, key market and key players. To present the Stem Cell Reconstructive development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America. To strategically profile the key players and comprehensively analyze their development plan and strategies. To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Stem Cell Reconstructive are as follows: History Year: 2015-2019 Base Year: 2019 Estimated Year: 2020 Forecast Year 2020 to 2026 For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2694263&source=atm

Opportunity assessment Provided in the Stem Cell Reconstructive Market report Is important concerning understanding the profitable regions of investment, which are the technical insights for major market players, suppliers, vendors, and other stakeholders in Stem Cell Reconstructive Market.

In-depth global Stem Cell Reconstructive Market taxonomy presented in this Report offers detailed insights about each of the market sections and their sub-segments, which are categorized based on par various parameters. An exhaustive regional evaluation of global Stem Cell Reconstructive Market divides international market landscape into essential geographies.

Regional outlook and country-wise evaluation of Stem Cell Reconstructive Market Allows for the evaluation of multi-faceted performance of market in all the crucial markets. This advice plans to provide a wider scope of report to readers and identify the most relevant profitable areas in global market place.

Key Regions and Countries Covered in Global Stem Cell Reconstructive Market Report-

Taxonomy and geographical analysis of the international Stem Cell Reconstructive Market empowers readers to spot profits in present chances and catch upcoming growth opportunities even until they approach the market location. The analysis given in report is only intended to unroll the economic, societal, regulatory and political scenarios of the marketplace specific to each area and country, which might help prospective market entrants in Stem Cell Reconstructive Market landscape to comprehend the nitty-gritty of target market regions and invent their strategies accordingly.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2694263&licType=S&source=atm

Major TOC Covered In this Report are:

Read the original:
Forecast On Stem Cell Reconstructive Market Global Industry Analysis and Trends till 2028 - Bulletin Line

‘Healthy’ mum diagnosed with cancer so aggressive it cracked several ribs – Mirror Online

A mum was left 'shocked' after being told by doctors she had cancer so aggressive it had cracked several of her ribs.

Susie Suter, who had been "fit and healthy" all her life, went to see a doctor after suffering with pain so severe in her chest and spine that she struggled to walk.

Hospital scans revealed that cancer had spread all over her body and damaged her spine and sternum, Wales Online reports.

Tragically, the disease had become so aggressive that small holes had formed in her vertebrae and the tumours had caused several of her ribs to crack.

"I'm so grateful that I was with my mother at the time because I was deeply shocked by the news," Susie said.

"I just couldn't believe it. I had been fit and healthy all my life and felt so young.

"I thought I was looking at a terminal illness. The consultant looked devastated when he told me."

After a series of tests at Nevill Hall Hospital inAbergavenny, Monmouthshire the mum-of-two was diagnosed with multiple myeloma, a cancer that develops in white blood cells called plasma cells.

"I was so relieved to have a diagnosis," admitted Susie, the owner of the Gliffaes Country House Hotel in Crickhowell, Powys.

"The worst bit was not knowing what it was and feeling so anxious about what would happen to me.

"My daughters were in the middle of their exams at school and I was worried about how they would feel. It was a relief to get some answers."

In August, 2013, at the age of 44, Susie had radiotherapy treatment at the Velindre Cancer Centre in Cardiff and was under the care of Nevill Hall Hospital for chemotherapy.

She was told her best chance of survival would be a stem cell transplant, so in March 2014 she underwent the transplant to help her body make new healthy blood cells after her own had been damaged by the disease.

Susie, wife to James Suter, 54, and mum to Alexandra, 25, and Olivia, 23, said: "I found this part of my treatment incredibly hard. I felt so sick and tired and I lost a lot of weight and eventually all my hair.

"It took me a long time to feel myself again after this, although the medical team were excellent and helped me to get through it."

Six months after the transplant, Susie said her energy levels had returned, and after a year she began to feel like she had done before her diagnosis.

In the years since she has accomplished several sporting and non-sporting challenges for charity, including a fundraising bike ride from London to Paris.

Ever since her transplant five years ago she has been on a Cancer Research UK-supported clinical research trial involving the drug Revlimid which has kept her feeling well.

But last year she suffered a blow when she was told she had relapsed and might need another stem cell transplant in the future. Susie currently has regular bone-strengthening treatments at Nevill Hall Hospital.

By sharing her remarkable story, Susie hopes to inspire people across Wales to donate to Cancer Research UK to get lifesaving work back on track.

"Research gives me, my family, and friends the hope we need," she said.

"It's thanks to improved treatments that I've been given more precious time with my loved ones. It upsets me to think about research being delayed and what this might mean for people affected by cancer in the months and years to come."

After the cancellation of fundraising events like Race for Life, Cancer Research UK is expecting a staggering 160m drop in income in the year ahead.

As a result, the charity said it had been forced to take the difficult decision to cut 44m in research funding -but this is likely to be just the beginning.

Cassandra Miles, Cancer Research UK spokeswoman for Wales, said: "Were grateful to Susie for helping to underline the stark reality of the current situation.

"Covid-19 put so much of our research on pause, leaving us facing a crisis where every day and every pound counts.

"With around 19,500 people diagnosed with cancer each year in Wales, we will never stop striving to create better treatments. But we cant do it alone.

"Whether they donate, sign up to Race for Life at Home or shop at our stores - with the help of people in Wales, we believe that together we will still beat cancer. Donate now at cruk.org/give."

Originally posted here:
'Healthy' mum diagnosed with cancer so aggressive it cracked several ribs - Mirror Online

Stem Cell Therapy Market Detailed Analysis of Current Industry Figures With Forecasts Growth by 2026|Osiris Therapeutics, NuVasive, Chiesi…

QY Research has Published Latest Trending Report on Global Stem Cell Therapy Market

Los Angeles, United State, The report titledGlobal Stem Cell Therapy Marketis one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Stem Cell Therapy market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Stem Cell Therapy market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Stem Cell Therapy market is carefully analyzed and researched about by the market analysts.

Request Sample Report and Full Report TOC:https://www.qyresearch.com/sample-form/form/1436410/global-stem-cell-therapy-market

The Essential Content Covered in the GlobalStem Cell Therapy Market Report:

* Top Key Company Profiles. * Main Business and Rival Information * SWOT Analysis and PESTEL Analysis * Production, Sales, Revenue, Price and Gross Margin * Market Share and Size

Global Stem Cell Therapy Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during 2020-2026. According to the latest report added to the online repository of QY Research the Stem Cell Therapy market has witnessed an unprecedented growth till 2020. The extrapolated future growth is expected to continue at higher rates by 2025.

Top Players of Stem Cell Therapy Market are Studied: Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix)

The report provides a 6-year forecast (2020-2026) assessed based on how the Stem Cell Therapy market is predicted to grow in major regions likeUSA, Europe, Japan, China, India, Southeast Asia, South America, South Africa, Others.

Segmentation by Type:Autologous Allogeneic

Segmentation by Application:Musculoskeletal Disorder Wounds & Injuries Cornea Cardiovascular Diseases Others

Reasons to Buy this Report:

Table of Contents

Table of Contents 1 Report Overview

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Stem Cell Therapy Revenue

1.4 Market Analysis by Type

1.4.1 Global Stem Cell Therapy Market Size Growth Rate by Type: 2020 VS 2026

1.4.2 Autologous

1.4.3 Allogeneic

1.5 Market by Application

1.5.1 Global Stem Cell Therapy Market Share by Application: 2020 VS 2026

1.5.2 Musculoskeletal Disorder

1.5.3 Wounds & Injuries

1.5.4 Cornea

1.5.5 Cardiovascular Diseases

1.5.6 Others 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions

2.1 Stem Cell Therapy Market Perspective (2015-2026)

2.2 Stem Cell Therapy Growth Trends by Regions

2.2.1 Stem Cell Therapy Market Size by Regions: 2015 VS 2020 VS 2026

2.2.2 Stem Cell Therapy Historic Market Share by Regions (2015-2020)

2.2.3 Stem Cell Therapy Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers

2.3.3 Market Challenges

2.3.4 Porters Five Forces Analysis

2.3.5 Stem Cell Therapy Market Growth Strategy

2.3.6 Primary Interviews with Key Stem Cell Therapy Players (Opinion Leaders) 3 Competition Landscape by Key Players

3.1 Global Top Stem Cell Therapy Players by Market Size

3.1.1 Global Top Stem Cell Therapy Players by Revenue (2015-2020)

3.1.2 Global Stem Cell Therapy Revenue Market Share by Players (2015-2020)

3.1.3 Global Stem Cell Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

3.2 Global Stem Cell Therapy Market Concentration Ratio

3.2.1 Global Stem Cell Therapy Market Concentration Ratio (CR5 and HHI)

3.2.2 Global Top 10 and Top 5 Companies by Stem Cell Therapy Revenue in 2019

3.3 Stem Cell Therapy Key Players Head office and Area Served

3.4 Key Players Stem Cell Therapy Product Solution and Service

3.5 Date of Enter into Stem Cell Therapy Market

3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)

4.1 Global Stem Cell Therapy Historic Market Size by Type (2015-2020)

4.2 Global Stem Cell Therapy Forecasted Market Size by Type (2021-2026) 5 Stem Cell Therapy Breakdown Data by Application (2015-2026)

5.1 Global Stem Cell Therapy Market Size by Application (2015-2020)

5.2 Global Stem Cell Therapy Forecasted Market Size by Application (2021-2026) 6 North America

6.1 North America Stem Cell Therapy Market Size (2015-2020)

6.2 Stem Cell Therapy Key Players in North America (2019-2020)

6.3 North America Stem Cell Therapy Market Size by Type (2015-2020)

6.4 North America Stem Cell Therapy Market Size by Application (2015-2020) 7 Europe

7.1 Europe Stem Cell Therapy Market Size (2015-2020)

7.2 Stem Cell Therapy Key Players in Europe (2019-2020)

7.3 Europe Stem Cell Therapy Market Size by Type (2015-2020)

7.4 Europe Stem Cell Therapy Market Size by Application (2015-2020) 8 China

8.1 China Stem Cell Therapy Market Size (2015-2020)

8.2 Stem Cell Therapy Key Players in China (2019-2020)

8.3 China Stem Cell Therapy Market Size by Type (2015-2020)

8.4 China Stem Cell Therapy Market Size by Application (2015-2020) 9 Japan

9.1 Japan Stem Cell Therapy Market Size (2015-2020)

9.2 Stem Cell Therapy Key Players in Japan (2019-2020)

9.3 Japan Stem Cell Therapy Market Size by Type (2015-2020)

9.4 Japan Stem Cell Therapy Market Size by Application (2015-2020) 10 Southeast Asia

10.1 Southeast Asia Stem Cell Therapy Market Size (2015-2020)

10.2 Stem Cell Therapy Key Players in Southeast Asia (2019-2020)

10.3 Southeast Asia Stem Cell Therapy Market Size by Type (2015-2020)

10.4 Southeast Asia Stem Cell Therapy Market Size by Application (2015-2020) 11 India

11.1 India Stem Cell Therapy Market Size (2015-2020)

11.2 Stem Cell Therapy Key Players in India (2019-2020)

11.3 India Stem Cell Therapy Market Size by Type (2015-2020)

11.4 India Stem Cell Therapy Market Size by Application (2015-2020) 12 Central & South America

12.1 Central & South America Stem Cell Therapy Market Size (2015-2020)

12.2 Stem Cell Therapy Key Players in Central & South America (2019-2020)

12.3 Central & South America Stem Cell Therapy Market Size by Type (2015-2020)

12.4 Central & South America Stem Cell Therapy Market Size by Application (2015-2020) 13Key Players Profiles

13.1 Osiris Therapeutics

13.1.1 Osiris Therapeutics Company Details

13.1.2 Osiris Therapeutics Business Overview and Its Total Revenue

13.1.3 Osiris Therapeutics Stem Cell Therapy Introduction

13.1.4 Osiris Therapeutics Revenue in Stem Cell Therapy Business (2015-2020))

13.1.5 Osiris Therapeutics Recent Development

13.2 NuVasive

13.2.1 NuVasive Company Details

13.2.2 NuVasive Business Overview and Its Total Revenue

13.2.3 NuVasive Stem Cell Therapy Introduction

13.2.4 NuVasive Revenue in Stem Cell Therapy Business (2015-2020)

13.2.5 NuVasive Recent Development

13.3 Chiesi Pharmaceuticals

13.3.1 Chiesi Pharmaceuticals Company Details

13.3.2 Chiesi Pharmaceuticals Business Overview and Its Total Revenue

13.3.3 Chiesi Pharmaceuticals Stem Cell Therapy Introduction

13.3.4 Chiesi Pharmaceuticals Revenue in Stem Cell Therapy Business (2015-2020)

13.3.5 Chiesi Pharmaceuticals Recent Development

13.4 JCR Pharmaceutical

13.4.1 JCR Pharmaceutical Company Details

Visit link:
Stem Cell Therapy Market Detailed Analysis of Current Industry Figures With Forecasts Growth by 2026|Osiris Therapeutics, NuVasive, Chiesi...

Stem Cells Market Study for 2020 to 2026 Providing Information on Key Players, Growth Drivers and Industry Challenges|CCBC, Vcanbio, Boyalife – Owned

QY Research has Published Latest Trending Report on Global Stem Cells Market

Los Angeles, United State, The report titledGlobal Stem Cells Marketis one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Stem Cells market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Stem Cells market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Stem Cells market is carefully analyzed and researched about by the market analysts.

Request Sample Report and Full Report TOC:https://www.qyresearch.com/sample-form/form/1436482/global-stem-cells-market

The Essential Content Covered in the GlobalStem Cells Market Report:

* Top Key Company Profiles. * Main Business and Rival Information * SWOT Analysis and PESTEL Analysis * Production, Sales, Revenue, Price and Gross Margin * Market Share and Size

Global Stem Cells Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during 2020-2026. According to the latest report added to the online repository of QY Research the Stem Cells market has witnessed an unprecedented growth till 2020. The extrapolated future growth is expected to continue at higher rates by 2025.

Top Players of Stem Cells Market are Studied: CCBC, Vcanbio, Boyalife, Beikebiotech,

The report provides a 6-year forecast (2020-2026) assessed based on how the Stem Cells market is predicted to grow in major regions likeUSA, Europe, Japan, China, India, Southeast Asia, South America, South Africa, Others.

Segmentation by Type:Umbilical Cord Blood Stem Cell Embryonic Stem Cell Adult Stem Cell Other

Segmentation by Application:Diseases Therapy Healthcare

Reasons to Buy this Report:

Table of Contents

Table of Contents 1 Report Overview

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Stem Cells Revenue

1.4 Market Analysis by Type

1.4.1 Global Stem Cells Market Size Growth Rate by Type: 2020 VS 2026

1.4.2 Umbilical Cord Blood Stem Cell

1.4.3 Embryonic Stem Cell

1.4.4 Adult Stem Cell

1.4.5 Other

1.5 Market by Application

1.5.1 Global Stem Cells Market Share by Application: 2020 VS 2026

1.5.2 Diseases Therapy

1.5.3 Healthcare 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions

2.1 Stem Cells Market Perspective (2015-2026)

2.2 Stem Cells Growth Trends by Regions

2.2.1 Stem Cells Market Size by Regions: 2015 VS 2020 VS 2026

2.2.2 Stem Cells Historic Market Share by Regions (2015-2020)

2.2.3 Stem Cells Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers

2.3.3 Market Challenges

2.3.4 Porters Five Forces Analysis

2.3.5 Stem Cells Market Growth Strategy

2.3.6 Primary Interviews with Key Stem Cells Players (Opinion Leaders) 3 Competition Landscape by Key Players

3.1 Global Top Stem Cells Players by Market Size

3.1.1 Global Top Stem Cells Players by Revenue (2015-2020)

3.1.2 Global Stem Cells Revenue Market Share by Players (2015-2020)

3.1.3 Global Stem Cells Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

3.2 Global Stem Cells Market Concentration Ratio

3.2.1 Global Stem Cells Market Concentration Ratio (CR5 and HHI)

3.2.2 Global Top 10 and Top 5 Companies by Stem Cells Revenue in 2019

3.3 Stem Cells Key Players Head office and Area Served

3.4 Key Players Stem Cells Product Solution and Service

3.5 Date of Enter into Stem Cells Market

3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)

4.1 Global Stem Cells Historic Market Size by Type (2015-2020)

4.2 Global Stem Cells Forecasted Market Size by Type (2021-2026) 5 Stem Cells Breakdown Data by Application (2015-2026)

5.1 Global Stem Cells Market Size by Application (2015-2020)

5.2 Global Stem Cells Forecasted Market Size by Application (2021-2026) 6 North America

6.1 North America Stem Cells Market Size (2015-2020)

6.2 Stem Cells Key Players in North America (2019-2020)

6.3 North America Stem Cells Market Size by Type (2015-2020)

6.4 North America Stem Cells Market Size by Application (2015-2020) 7 Europe

7.1 Europe Stem Cells Market Size (2015-2020)

7.2 Stem Cells Key Players in Europe (2019-2020)

7.3 Europe Stem Cells Market Size by Type (2015-2020)

7.4 Europe Stem Cells Market Size by Application (2015-2020) 8 China

8.1 China Stem Cells Market Size (2015-2020)

8.2 Stem Cells Key Players in China (2019-2020)

8.3 China Stem Cells Market Size by Type (2015-2020)

8.4 China Stem Cells Market Size by Application (2015-2020) 9 Japan

9.1 Japan Stem Cells Market Size (2015-2020)

9.2 Stem Cells Key Players in Japan (2019-2020)

9.3 Japan Stem Cells Market Size by Type (2015-2020)

9.4 Japan Stem Cells Market Size by Application (2015-2020) 10 Southeast Asia

10.1 Southeast Asia Stem Cells Market Size (2015-2020)

10.2 Stem Cells Key Players in Southeast Asia (2019-2020)

10.3 Southeast Asia Stem Cells Market Size by Type (2015-2020)

10.4 Southeast Asia Stem Cells Market Size by Application (2015-2020) 11 India

11.1 India Stem Cells Market Size (2015-2020)

11.2 Stem Cells Key Players in India (2019-2020)

11.3 India Stem Cells Market Size by Type (2015-2020)

11.4 India Stem Cells Market Size by Application (2015-2020) 12 Central & South America

12.1 Central & South America Stem Cells Market Size (2015-2020)

12.2 Stem Cells Key Players in Central & South America (2019-2020)

12.3 Central & South America Stem Cells Market Size by Type (2015-2020)

12.4 Central & South America Stem Cells Market Size by Application (2015-2020) 13Key Players Profiles

13.1 CCBC

13.1.1 CCBC Company Details

13.1.2 CCBC Business Overview and Its Total Revenue

13.1.3 CCBC Stem Cells Introduction

13.1.4 CCBC Revenue in Stem Cells Business (2015-2020))

13.1.5 CCBC Recent Development

13.2 Vcanbio

13.2.1 Vcanbio Company Details

13.2.2 Vcanbio Business Overview and Its Total Revenue

13.2.3 Vcanbio Stem Cells Introduction

13.2.4 Vcanbio Revenue in Stem Cells Business (2015-2020)

13.2.5 Vcanbio Recent Development

13.3 Boyalife

13.3.1 Boyalife Company Details

13.3.2 Boyalife Business Overview and Its Total Revenue

13.3.3 Boyalife Stem Cells Introduction

13.3.4 Boyalife Revenue in Stem Cells Business (2015-2020)

13.3.5 Boyalife Recent Development

13.4 Beikebiotech

13.4.1 Beikebiotech Company Details

13.4.2 Beikebiotech Business Overview and Its Total Revenue

Continued here:
Stem Cells Market Study for 2020 to 2026 Providing Information on Key Players, Growth Drivers and Industry Challenges|CCBC, Vcanbio, Boyalife - Owned

Animal Stem Cell Therapy Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2017 2025 – Bulletin Line

Evaluation of the Global Animal Stem Cell Therapy Market

The presented study maps the growth trajectory of the global Animal Stem Cell Therapy market by thoroughly assessing the various factors that are expected to influence the future prospects of the Animal Stem Cell Therapy market. According to the report published by PMR, the Animal Stem Cell Therapy market is poised to attain a value of ~US$ XX Mn/Bn by the end of 2029 with a CAGR growth of ~XX% during the forecast period (2019-2029).

A complete evaluation of the trends, market drivers, opportunities, and challenges faced by market players operating in the Animal Stem Cell Therapy market is provided in the report. Further, an overview and introduction of the Animal Stem Cell Therapy market is included to ensure that the readers have a seamless experience while going through the contents of the report.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/14941

Critical insights included in the report:

Competitive Outlook

The competitive outlook assessment provides an in-depth understanding related to the business proceeding of top-tier market players in the global Animal Stem Cell Therapy market. The product portfolio, sales strategy, marketing & promotional strategy, and sales footprint of each market player is scrutinized thoroughly in the report. Some of the leading players evaluated in the report include:

The report segments the global Animal Stem Cell Therapy market on the basis of region, product type, and end use.

Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

The report covers exhaustive analysis on:

Regional analysis for Market includes

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/14941

Regional Analysis

The market scenario in each region along with a comprehensive assessment of the micro and macro-economic factors that are forecasted to impact the market growth in these regions is included in the report.

End Use Assessment

The market study offers accurate and in-depth analysis of the various end uses of the Animal Stem Cell Therapy along with a yearly comparison of the market share and revenue growth of each end use.

Important queries addressed in the report:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/14941

Why Opt for PMR?

Read more:
Animal Stem Cell Therapy Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2017 2025 - Bulletin Line

AIIMS Delhi Indias best medical college thats home to many leaders of Covid battle – ThePrint

Text Size: A- A+

New Delhi: Theres much in common among AIIMS director Randeep Guleria, cardiologist Balram Bhargava, who heads the Indian Council of Medical Research (ICMR), V.K. Paul of the government thinktank Niti Aayog, WHO chief scientist Soumya Swaminathan, and Public Health Foundation of India (PHFI) president Dr Srinath Reddy, who is also on the steering committee of the WHO-led Solidarity trial to look for an effective Covid-19 treatment.

These luminaries of the medical field are all playing an important role in handling the biggest health crisis the world has faced in decades, Covid-19. But thats not it. All of them have either taught or studied at AIIMS Delhi, the premier medical facility from the early years of Independent India that continues to top the governments medical college rankings year after year, including in 2020.

Everyone in India from the low-income patients who throng the hospitals OPD for its promise of affordable care, to VIPs who cut through lines for treatment knows AIIMS is the best in the country.

But its reputation doesnt necessarily come from the functions it performs as a hospital, doctors and students say. It comes from AIIMS ability to produce award-winning physicians year after year.

But what exactly is it that makes AIIMS the best medical institution in a country that has over 540 medical colleges and is known for exporting doctors to countries around the world?

Also Read: Fever not predominant Covid symptom, focus on it may lead to missing cases, says AIIMS study

Dr P.K. Julka, an oncologist who retired from the institute as dean in 2016, says everything is top of the line at AIIMS. From equipment to medical protocols, and, most importantly, the freedom to pursue your research interests, he added.

We are deeply grateful to our readers & viewers for their time, trust and subscriptions.

Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrints future.

SUBSCRIBE NOW

Like so many of the institutes alumni, Julka has had an illustrious career: He was the first to conduct a peripheral blood stem cell transplant in the country (1995), and was awarded the Padmi Shri for his contributions to medicine in 2013. AIIMS made this possible, he added.

The foundation stone of AIIMS Delhi was laid in 1952, and it came into being as an autonomous institution through the AIIMS Act, 1956.

It was crafted in line with the vision of Indias first prime minister, Jawaharlal Nehru, and first Health Minister Rajkumari Amrit Kaur, in whose honour the hospitals OPD is named.

AIIMS was among Nehrus temples of modern India, set up to serve as a centre for excellence in the medical sciences. From the time of its christening, it was decided that it would be the best, and everyone associated with it treated it as such.

Rajkumari fashioned it like a gurukul: Students and teachers would stay together within this same learning space. It was her pet project, said Dr Chandrakant Pandav, professor of community medicine who joined AIIMS in 1971 as an undergraduate. Bright Indians who had gone abroad to study medicine were called back to serve their country.

AIIMS was primarily a research and teaching centre in the first few years of being set up, but began rapidly expanding in the mid-to-late 1980s.

Managing patients has always been a problem. Earlier, we had fewer patients but were short on faculty. Now the number of patients who come is barely manageable despite having hundreds of doctors, said Julka. It has made prioritising time, between patient care, teaching, and research, more difficult.

In 2003, the Government of India resolved to correct the imbalances of tertiary care availability and allowed the formation of six AIIMS-like institutions, a decision cemented by an ordinance in 2012 and subsequently an amendment legislation.

Since then, the number of AIIMS-like institutions has grown to 15. Another eight are in development. However, while they carry the brand, they dont quite evoke the same respect, say doctors.

The institutes are not comparable, they have miles to go before they reach where AIIMS Delhi is. Thats because they dont have the same work culture that is already there in Delhi. The work culture is like a wave in the ocean, and they dont have it, Julka added.

Also Read: AIIMS Delhi and Raipur doctors question ICMR study that showed HCQ can curb Covid risk

For incoming students, the opportunity to study at AIIMS is both intimidating and exciting. Youre prepared for that pressure, said Mehek Arora, a second-year MBBS student at AIIMS, referring to the performance pressure. Once you begin classes, you fall into the rhythm of things and get used to it.

The 115-acre campus in Delhi houses 43 departments and has over 1,700 students both undergraduate and postgraduate. Students say that juniors and seniors interact freely, without the fear of ragging that has become a big worry at Indias medical colleges. While the average student-teacher ratio is 29:1 in India (2018-19), it was estimated to be 6:1 at AIIMS in 2016. The goal of bettering academic performance is common, and so the environment is studious and buoyant, insiders say.

At AIIMS, youre exposed to patients at an early stage, newly developed medical protocols, emerging research. When something new comes out of the US, we hear about it within a week. Theres no spoon-feeding, but theres a lot of space to learn and grow, said Giridhar Gopal, a PhD scholar in the field of community medicine.

Gopal did his MBBS from a government medical college at Kanjanur in Tamil Nadu, before coming to AIIMS in 2012 for his MD. Studying is not a burden here. Its what keeps the community buzzing.

According to old-timer Pandav, it is the sanctity of the student-teacher relationship that lies at the crux of AIIMS functioning. The focus, when he first arrived, was on teaching and the freedom to teach, he said.

The roots of AIIMS lie in its emphasis on teaching and research. Students and teachers used to be like family, because it was the best students, and the best teachers, coming together to serve the public, Pandav added.

The prestige of an AIIMS admission, combined with the fact that students and teachers have the best medical equipment and a free hand to conduct research, has kept the learning process novel.

In peripheral colleges, you really dont get access to the same information or leading protocols. Everything comes much later, whereas in AIIMS its all happening in real time, said Gopal.

But AIIMS exclusivity also lends it a clique-like aura where outsiders may not be immediately accepted, some people say.

Dr Shobha Broor, a retired virologist who taught at the institute for 27 years, says being accepted as an outsider takes time.

It took some time for them to accept me. I joined as an additional professor from PGIMS in Chandigarh. Initially, this was difficult to deal with, but I worked hard, and earned my place. The quality of students is what really makes the institute, she said.

Also Read: Dont know Delhi, had nothing to eat AIIMS buries 7-month-old as family heads home to MP

A rising number of patients isnt the only problem AIIMS has faced over the years. It has also been marred with allegations of caste bias.

In 2007, after a massive protest over allegations that Dalit students were being failed in their examinations, AIIMS became the first higher education institution in India where systemic caste discrimination and abuse was investigated, resulting in the Thorat Committee Report.

The report found that 72 per cent of SC students felt discriminated against during teaching lessons. While reforms have ensured there is no longer outright discrimination, professors told ThePrint in 2019 that subtle caste biases still exist.

Even though AIIMS produces an average of 700 research papers a year, its global ranking in the area remains relatively low: According to the QS World University Rankings for Life Sciences and Medicine, AIIMS is ranked 231. For comparison, Harvard University stands at number one.

With the sheer number of patients, the same interest in research and teaching is slowly disappearing, said Pandav. Clinical practice is taking precedence. Why do you think we havent won any Nobel prizes yet?

The institute is currently hosting a series of video sessions, called the Grand Round, sharing its experiences of tackling Covid-19 with hospitals across the world. It is hosting a vaccine trial, and holding telemedicine sessions with doctors from other institutes who need guidance. The path ahead is uncertain, but Pandav puts it well, The future of AIIMS lies in its past.

Also Read: Deprived of sisters body for burial after AIIMS mix-up, Muslim family cant find her ashes either

Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the medias economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the countrys most robust editing and fact-checking team, finest news photographers and video professionals. We are building Indias most ambitious and energetic news platform. And we arent even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrints future. It will take just a few seconds of your time.

Support Our Journalism

Visit link:
AIIMS Delhi Indias best medical college thats home to many leaders of Covid battle - ThePrint

Science May Have Finally Explained The Reason Why We Still Get Goosebumps – ScienceAlert

We all know what goosebumps are, but why have we evolved to hang on to this seemingly pointless physical reaction to the cold? New research suggests an answer: regulating stem cells that control hair follicles and hair growth.

In a detailed analysis of mice, scientists found that the specific muscles that contract when goosebumps appear are connected to the sympathetic nervous system. When low temperatures are sensed, these muscles bridge the gap between sympathetic nerves and hair follicles.

In the short term, it causes hair to stand up and goosebumps to appear; in the long term, it appears to promote hair growth. The researchers say this is an important link between stem cells which the body can use to create other kinds of cells and external stimuli.

(Hsu Laboratory/Harvard University)

Above: Hair follicle, sympathetic nerve (green), and muscle (magenta) under the microscope.

"The skin is a fascinating system," says biologist Ya-Chieh Hsufrom Harvard University. "It has multiple stem cells surrounded by diverse cell types, and is located at the interface between our body and the outside world. Therefore, its stem cells could potentially respond to a diverse array of stimuli from the niche, the whole body, or even the outside environment.

"In this study, we identify an interesting dual-component niche that not only regulates the stem cells under steady state, but also modulates stem cell behaviours according to temperature changes outside."

The team of researchers used high-resolution electron microscopy to identify this hair-growth regulation system, which involves the three types of tissue found in many organs: nerves (the sympathetic nerve), mesenchyme (holding the small muscles), and epithelium (the hair follicle stem cells).

While the connection between nerve and muscle was already known in this specific system, the link to the hair-regulating stem cells is a new discovery, and an unusual one neurons tend to prefer connections to other neurons or synapse-like connections to muscles. Here, those synapse-like connections are made to stem cells instead, wrapping around them like ribbons.

(Shwartz et al., Cell, 2020)

Above: How the muscle (pink), the sympathetic nerve (green), and the hair follicle stem cells (blue) react to cold.

The research also showed how prolonged cold puts the sympathetic nerves in a state of high alert, above the normal low-level activation that they spend most of their time at. More neurotransmitters are released, triggering quicker activation of the stem cells and, ultimately, quicker hair growth.

On top of that, the team established that the muscle was indeed an essential link between nerves and follicle stem cells when the muscle was removed, the connection was lost. The growth of the muscles is actually triggered by the hair follicles themselves, according to the activity observed in mice, anyway.

"We discovered that the signal comes from the developing hair follicle itself," says biologist Yulia Shwartz. "It secretes a protein that regulates the formation of the smooth muscle, which then attracts the sympathetic nerve.

"Then, in the adult, the interaction turns around, with the nerve and muscle together regulating the hair follicle stem cells to regenerate the new hair follicle. It's closing the whole circle the developing hair follicle is establishing its own niche."

While these same interactions haven't been observed in humans yet, biological similarities between mice and other mammals in this area make it likely that the same processes are going on underneath our own skin and that's why we can still get goosebumps.

This same tightening of muscles around hair follicles causes the little bumps on your skin to appear, and scientists think that back in the days when we were a lot hairier as a species, it would have provided some immediate defence against the cold. Now, an additional long-term strategy has also been revealed.

The researchers intend to do further work on the interaction between external environments and the stem cells in the skin, including looking at any other possible reactions that might be going on that we don't know about.

"We live in a constantly changing environment," says Hsu. "Since the skin is always in contact with the outside world, it gives us a chance to study what mechanisms stem cells in our body use to integrate tissue production with changing demands, which is essential for organisms to thrive in this dynamic world."

The research has been published in Cell.

More:
Science May Have Finally Explained The Reason Why We Still Get Goosebumps - ScienceAlert

Germ cell – Wikipedia

A germ cell is any biological cell that gives rise to the gametes of an organism that reproduces sexually. In many animals, the germ cells originate in the primitive streak and migrate via the gut of an embryo to the developing gonads. There, they undergo meiosis, followed by cellular differentiation into mature gametes, either eggs or sperm. Unlike animals, plants do not have germ cells designated in early development. Instead, germ cells can arise from somatic cells in the adult (such as the floral meristem of flowering plants).[1][2][3]

Multicellular eukaryotes are made of two fundamental cell types. Germ cells produce gametes and are the only cells that can undergo meiosis as well as mitosis. These cells are sometimes said to be immortal because they are the link between generations. Somatic cells are all the other cells that form the building blocks of the body and they only divide by mitosis. The lineage of germ cells is called germ line. Germ cell specification begins during cleavage in many animals or in the epiblast during gastrulation in birds and mammals. After transport, involving passive movements and active migration, germ cells arrive at the developing gonads. In humans, sexual differentiation starts approximately 6 weeks after conception. The end-products of the germ cell cycle are the egg or sperm.[4]

Under special conditions in vitro germ cells can acquire properties similar to those of embryonic stem cells (ES). The underlying mechanism of that change is still unknown. These changed cells are then called embryonic germ cells (EG). Both EG and ES are pluripotent in vitro, but only ES has proven pluripotency in vivo. Recent studies have demonstrated that it is possible to give rise to primordial germ cells from ES.[5]

There are two mechanisms to establish the germ cell lineage in the embryo. The first way is called preformistic and involves that the cells destined to become germ cells inherit the specific germ cell determinants present in the germ plasm (specific area of the cytoplasm) of the egg (ovum). The unfertilized egg of most animals is asymmetrical: different regions of the cytoplasm contain different amounts of mRNA and proteins.

The second way is found in mammals, where germ cells are not specified by such determinants but by signals controlled by zygotic genes. In mammals, a few cells of the early embryo are induced by signals of neighboring cells to become primordial germ cells. Mammalian eggs are somewhat symmetrical and after the first divisions of the fertilized egg, the produced cells are all totipotent. This means that they can differentiate in any cell type in the body and thus germ cells. Specification of primordial germ cells in the laboratory mouse is initiated by high levels of bone morphogenetic protein (BMP) signaling, which activates expression of the transcription factors Blimp-1/Prdm1 and Prdm14.[6]

It is speculated that induction was the ancestral mechanism, and that the preformistic, or inheritance, mechanism of germ cell establishment arose from convergent evolution.[7] There are several key differences between these two mechanisms that may provide reasoning for the evolution of germ plasm inheritance. One difference is that typically inheritance occurs almost immediately during development (around the blastoderm stage) while induction typically does not occur until gastrulation. As germ cells are quiescent and therefore not dividing, they are not susceptible to mutation.

Since the germ cell lineage is not established right away by induction, there is a higher chance for mutation to occur before the cells are specified. Mutation rate data is available that indicates a higher rate of germ line mutations in mice and humans, species which undergo induction, than in C. elegans and Drosophila melanogaster, species which undergo inheritance.[8] A lower mutation rate would be selected for, which is one possible reason for the convergent evolution of the germ plasm. However, more mutation rate data will need to be collected across several taxa, particularly data collected both before and after the specification of primordial germ cells before this hypothesis on the evolution of germ plasm can be backed by strong evidence.

Primordial germ cells, germ cells that still have to reach the gonads, also known as PGCs, precursor germ cells or gonocytes, divide repeatedly on their migratory route through the gut and into the developing gonads.[9]

In the model organism Drosophila, pole cells passively move from the posterior end of the embryo to the posterior midgut because of the infolding of the blastoderm. Then they actively move through the gut into the mesoderm. Endodermal cells differentiate and together with Wunen proteins they induce the migration through the gut. Wunen proteins are chemorepellents that lead the germ cells away from the endoderm and into the mesoderm. After splitting into two populations, the germ cells continue migrating laterally and in parallel until they reach the gonads. Columbus proteins, chemoattractants, stimulate the migration in the gonadal mesoderm.[citation needed]

In the Xenopus egg, the germ cell determinants are found in the most vegetal blastomeres. These presumptive PGCs are brought to the endoderm of the blastocoel by gastrulation. They are determined as germ cells when gastrulation is completed. Migration from the hindgut along the gut and across the dorsal mesentery then takes place. The germ cells split into two populations and move to the paired gonadal ridges. Migration starts with 3-4 cells that undergo three rounds of cell division so that about 30 PGCs arrive at the gonads. On the migratory path of the PGCs, the orientation of underlying cells and their secreted molecules such as fibronectin play an important role.[citation needed]

Mammals have a migratory path comparable to that in Xenopus. Migration begins with 50 gonocytes and about 5,000 PGCs arrive at the gonads. Proliferation occurs also during migration and lasts for 34 weeks in humans.[citation needed]

PGCs come from the epiblast and migrate subsequently into the mesoderm, the endoderm and the posterior of the yolk sac. Migration then takes place from the hindgut along the gut and across the dorsal mesentery to reach the gonads (4.5 weeks in human beings). Fibronectin maps here also a polarized network together with other molecules. The somatic cells on the path of germ cells provide them attractive, repulsive, and survival signals. But germ cells also send signals to each other.[citation needed]

In reptiles and birds, germ cells use another path. PGCs come from the epiblast and move to the hypoblast to form the germinal crescent (anterior extraembryonic structure). The gonocytes then squeeze into blood vessels and use the circulatory system for transport. They squeeze out of the vessels when they are at height of the gonadal ridges. Cell adhesion on the endothelium of the blood vessels and molecules such as chemoattractants are probably involved in helping PGCs migrate.[citation needed]

The SRY (Sex-determining Region of the Y chromosome) directs male development in mammals by inducing the somatic cells of the gonadal ridge to develop into a testis, rather than an ovary.[10]Sry is expressed in a small group of somatic cells of the gonads and influences these cells to become Sertoli cells (supporting cells in testis). Sertoli cells are responsible for sexual development along a male pathway in many ways. One of these ways involves stimulation of the arriving primordial cells to differentiate into sperm. In the absence of the Sry gene, primordial germ cells differentiate into eggs. Removing genital ridges before they start to develop into testes or ovaries results in the development of a female, independent of the carried sex chromosome.[10]

Retinoic acid (RA) is an important factor that causes differentiation of primordial germ cells. In males, the mesonephros releases retinoic acid. RA then goes to the gonad causing an enzyme called CYP26B1 to be released by sertoli cells. CYP26B1 metabolizes RA, and because sertoli cells surround primordial germ cells (PGCs), PGCs never come into contact with RA, which results in a lack of proliferation of PGCs and no meiotic entry. This keeps spermatogenesis from starting too soon. In females, the mesonephros releases RA, which enters the gonad. RA stimulates Stra8, a critical gatekeeper of meiosis (1), and Rec8, causing primordial germ cells to enter meiosis. This causes the development of oocytes that arrest in meiosis I. [11]

Gametogenesis, the development of diploid germ cells into either haploid eggs or sperm (respectively oogenesis and spermatogenesis) is different for each species but the general stages are similar. Oogenesis and spermatogenesis have many features in common, they both involve:

Despite their homologies they also have major differences:[citation needed]

After migration primordial germ cells will become oogonia in the forming gonad (ovary). The oogonia proliferate extensively by mitotic divisions, up to 5-7 million cells in humans. But then many of these oogonia die and about 50,000 remain. These cells differentiate into primary oocytes. In week 11-12 post coitus the first meiotic division begins (before birth for most mammals) and remains arrested in prophase I from a few days to many years depending on the species. It is in this period or in some cases at the beginning of sexual maturity that the primary oocytes secrete proteins to form a coat called zona pellucida and they also produce cortical granules containing enzymes and proteins needed for fertilization. Meiosis stands by because of the follicular granulosa cells that send inhibitory signals through gap junctions and the zona pellucida. Sexual maturation is the beginning of periodic ovulation. Ovulation is the regular release of one oocyte from the ovary into the reproductive tract and is preceded by follicular growth. A few follicle cells are stimulated to grow but only one oocyte is ovulated. A primordial follicle consists of an epithelial layer of follicular granulosa cells enclosing an oocyte. The pituitary gland secrete follicle-stimulating hormones (FSHs) that stimulate follicular growth and oocyte maturation. The thecal cells around each follicle secrete estrogen. This hormone stimulates the production of FSH receptors on the follicular granulosa cells and has at the same time a negative feedback on FSH secretion. This results in a competition between the follicles and only the follicle with the most FSH receptors survives and is ovulated. Meiotic division I goes on in the ovulated oocyte stimulated by luteinizing hormones (LHs) produced by the pituitary gland. FSH and LH block the gap junctions between follicle cells and the oocyte therefore inhibiting communication between them. Most follicular granulosa cells stay around the oocyte and so form the cumulus layer. Large non-mammalian oocytes accumulate egg yolk, glycogen, lipids, ribosomes, and the mRNA needed for protein synthesis during early embryonic growth. These intensive RNA biosynthese are mirrored in the structure of the chromosomes, which decondense and form lateral loops giving them a lampbrush appearance (see Lampbrush chromosome). Oocyte maturation is the following phase of oocyte development. It occurs at sexual maturity when hormones stimulate the oocyte to complete meiotic division I. The meiotic division I produces 2 cells differing in size: a small polar body and a large secondary oocyte. The secondary oocyte undergoes meiotic division II and that results in the formation of a second small polar body and a large mature egg, both being haploid cells. The polar bodies degenerate.[12] Oocyte maturation stands by at metaphase II in most vertebrates. During ovulation, the arrested secondary oocyte leaves the ovary and matures rapidly into an egg ready for fertilization. Fertilization will cause the egg to complete meiosis II. In human females there is proliferation of the oogonia in the fetus, meiosis starts then before birth and stands by at meiotic division I up to 50 years, ovulation begins at puberty.[citation needed]

A 10 - 20 m large somatic cell generally needs 24 hours to double its mass for mitosis. By this way it would take a very long time for that cell to reach the size of a mammalian egg with a diameter of 100 m (some insects have eggs of about 1,000 m or greater). Eggs have therefore special mechanisms to grow to their large size. One of these mechanisms is to have extra copies of genes: meiotic division I is paused so that the oocyte grows while it contains two diploid chromosome sets. Some species produce many extra copies of genes, such as amphibians, which may have up to 1 or 2 million copies. A complementary mechanism is partly dependent on syntheses of other cells. In amphibians, birds, and insects, yolk is made by the liver (or its equivalent) and secreted into the blood. Neighboring accessory cells in the ovary can also provide nutritive help of two types. In some invertebrates some oogonia become nurse cells. These cells are connected by cytoplasmic bridges with oocytes. The nurse cells of insects provide oocytes macromolecules such as proteins and mRNA. Follicular granulosa cells are the second type of accessory cells in the ovary in both invertebrates and vertebrates. They form a layer around the oocyte and nourish them with small molecules, no macromolecules, but eventually their smaller precursor molecules, by gap junctions.[citation needed]

The mutation frequency of female germline cells in mice is about 5-fold lower than that of somatic cells, according to one study.[13]

The mouse oocyte in the dictyate (prolonged diplotene) stage of meiosis actively repairs DNA damage, whereas DNA repair was not detected in the pre-dictyate (leptotene, zygotene and pachytene) stages of meiosis.[14] The long period of meiotic arrest at the four chromatid dictyate stage of meiosis may facilitate recombinational repair of DNA damages.[15]

Mammalian spermatogenesis is representative for most animals. In human males, spermatogenesis begins at puberty in seminiferous tubules in the testicles and go on continuously. Spermatogonia are immature germ cells. They proliferate continuously by mitotic divisions around the outer edge of the seminiferous tubules, next to the basal lamina. Some of these cells stop proliferation and differentiate into primary spermatocytes. After they proceed through the first meiotic division, two secondary spermatocytes are produced. The two secondary spermatocytes undergo the second meiotic division to form four haploid spermatids. These spermatids differentiate morphologically into sperm by nuclear condensation, ejection of the cytoplasm and formation of the acrosome and flagellum.[citation needed]

The developing male germ cells do not complete cytokinesis during spermatogenesis. Consequently, cytoplasmic bridges assure connection between the clones of differentiating daughter cells to form a syncytium. In this way the haploid cells are supplied with all the products of a complete diploid genome. Sperm that carry a Y chromosome, for example, is supplied with essential molecules that are encoded by genes on the X chromosome.[citation needed]

Success of germ cell proliferation and differentiation is also ensured by a balance between germ cell development and programmed cell death. Identification of death triggering signals and corresponding receptor proteins is important for the fertilization potential of males. Apoptosis in germ cells can be induced by variety of naturally occurring toxicant. Receptors belonging to the taste 2 family are specialized to detect bitter compounds including extremely toxic alkaloids. So taste receptors play a functional role for controlling apoptosis in male reproductive tissue. [16]

The mutation frequencies for cells throughout the different stages of spermatogenesis in mice is similar to that in female germline cells, that is 5 to 10-fold lower than the mutation frequency in somatic cells[17][13] Thus low mutation frequency is a feature of germline cells in both sexes. Homologous recombinational repair of double-strand breaks occurs in mouse during sequential stages of spermatogenesis, but is most prominent in spermatocytes.[15] The lower frequencies of mutation in germ cells compared to somatic cells appears to be due to more efficient removal of DNA damages by repair processes including homologous recombination repair during meiosis.[citation needed] Mutation frequency during spermatogenesis increases with age.[17] The mutations in spermatogenic cells of old mice include an increased prevalence of transversion mutations compared to young and middle-aged mice.[18]

Germ cell tumor is a rare cancer that can affect people at all ages. As of 2018, germ cell tumors account for 3% of all cancers in children and adolescents 0-19 years old.[19]

Germ cell tumors are generally located in the gonads but can also appear in the abdomen, pelvis, mediastinum, or brain. Germ cells migrating to the gonads may not reach that intended destination and a tumor can grow wherever they end up, but the exact cause is still unknown. These tumors can be benign or malignant.[20]

On arrival at the gonad, primordial germ cells that do not properly differentiate may produce germ cell tumors of the ovary or testis in a mouse model.[21]

Inducing differentiation of certain cells to germ cells has many applications. One implication of induced differentiation is that it may allow for the eradication of male and female factor infertility. Furthermore, it would allow same-sex couples to have biological children if sperm could be produced from female cells or if eggs could be produced from male cells. Efforts to create sperm and eggs from skin and embryonic stem cells were pioneered by Hayashi and Saitou's research group at Kyoto University.[22] These researchers produced primordial germ cell-like cells (PGLCs) from embryonic stem cells (ESCs) and skin cells in vitro.

Hayashi and Saitou's group was able to promote the differentiation of embryonic stem cells into PGCs with the use of precise timing and bone morphogenetic protein 4 (Bmp4). Upon succeeding with embryonic stem cells, the group was able to successfully promote the differentiation of induced pluripotent stem cells (iPSCs) into PGLCs. These primordial germ cell-like cells were then used to create spermatozoa and oocytes.[23]

Efforts for human cells are less advanced due to the fact that the PGCs formed by these experiments are not always viable. In fact Hayashi and Saitou's method is only one third as effective as current in vitro fertilization methods, and the produced PGCs are not always functional. Furthermore, not only are the induced PGCs not as effective as naturally occurring PGCs, but they are also less effective at erasing their epigenetic markers when they differentiate from iPSCs or ESCs to PGCs.

There are also other applications of induced differentiation of germ cells. Another study showed that culture of human embryonic stem cells in mitotically inactivated porcine ovarian fibroblasts (POF) causes differentiation into germ cells, as evidenced by gene expression analysis.[24]

Originally posted here:
Germ cell - Wikipedia

COVID-19 Fibroblast Based Cell Therapy Candidate Shown to Reduce Lung Scarring in Aggressive Animal Model – El Paso Inc.

HOUSTON, July 21, 2020 /PRNewswire/ --FibroGenesis announced today new data supporting use of its PneumoBlast product in the battle against COVID-19.Using the widely accepted bleomycin model of lung scarring (fibrosis), Company scientists have demonstrated the administration and use of PneumoBlast induced a 51% reduction of lung fibrosis,which was statistically significant (p < .005). Importantly, when PneumoBlast was compared head to head with bone marrow derived mesenchymal stem cells (BMSCs) for COVID-19, PneumoBlast was 221% more effective. In producing the potent anti-inflammatory protein interleukin 1 receptor antagonist, which is believed to be the mechanism of scar tissue prevention by BMSC therapies currently in development, PneumoBlast was 192% more effective than BMSCs which was again, statistically significant(p < .005).

During an interview with Healthline.com, Dr. Lori Shah, transplant pulmonologist at New York-Presbyterian/Columbia University Irving Medical Center, stated "Holes in the lungs likely refers to an entity that has been dubbed 'post-COVID fibrosis,' otherwise known as post-ARDS [acute respiratory distress syndrome] fibrosis, which is irreversible and can result in severe functional limitations from patients, such as cough, shortness of breath, and need for oxygen." It has been reported that pulmonary fibrosis due to COVID-19 is occurring in increasing numbers of patients in their 20s and 30s.

"COVID-19 represents a new clinical entity which not only causes death through lung inflammation, but in some patients causes permanent lung injury through stimulation of scarring," said Tom Ichim, Ph.D., Chief Scientific Officer of FibroGenesis. "The prospects that our cell therapy approach not only possesses therapeutic effects on animal models of the acute stage of COVID-19, but also benefits the long-term pathology, has our research team extremely excited."

"As the scientific and medical community is discovering more about the biological and medical consequences of the COVID-19 infection, FibroGenesis is eager to contribute to the therapeutic cure options currently being created to fight this global war against an invisible enemy," commented Pete O'Heeron, President/CEO of FibroGenesis. "While we are excited about potential vaccines in the pipeline, the fact remains that there are 3.8 million confirmed cases of COVID-19 in the U.S. and we do not know what the long-term outcomes for these patients will be. To our knowledge, we are the only cell therapy company which is creating a therapy to resolve the initial pathology of infection and also proactively tackling its long-term consequences."

About FibroGenesis

Based in Houston, Texas, FibroGenesis, is a regenerative medicine company developing an innovative solution for chronic disease treatment using human dermal fibroblasts. Currently, FibroGenesis holds 235+ U.S. and international issued patents/patents pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson's, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure, Colitis and Heart Failure. Funded entirely by angel investors, FibroGenesis represents the next generation of medical advancement in cell therapy.

Visit http://www.Fibro-Genesis.com.

Follow this link:
COVID-19 Fibroblast Based Cell Therapy Candidate Shown to Reduce Lung Scarring in Aggressive Animal Model - El Paso Inc.